Filgrastim-aafi Intravenous, Subcutaneous and Tazarotene

• Generic Name: filgrastim
• Dosage Forms: n.a.
• Other Brand Names: Neupogen, Neupogen SingleJect, Nivestym, Zarxio

Filgrastim-aafi injection is used to treat neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in your body called a colony stimulating factor. Filgrastim-aafi helps the bone marrow to make new white blood cells.

When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim-aafi is used to prevent or reduce the risk of infections while you are being treated with cancer medicines. Filgrastim-aafi is also used to help the bone marrow recover after a bone marrow transplantation, for a process called peripheral blood progenitor cell collection in cancer patients.

Filgrastim-aafi is available only with your doctor's prescription.

• Generic Name: tazarotene topical
• Dosage Forms: n.a.
• Other Brand Names: Avage, Fabior, Tazorac

Treatment of stable plaque psoriasis with ≤20% body surface area involvement.

Combination therapy with a mid-or high-potency topical corticosteroid more effective than either agent alone.

0.1% cream or gel more effective in improving psoriasis manifestations; 0.05% cream or gel associated with less local irritation.

Treatment of mild to moderate acne vulgaris.

Efficacy in patients resistant to oral antibiotics or previously treated with other retinoids not established.

Palliative therapy to improve dermatologic changes (e.g., fine wrinkling, mottled hypo- or hyperpigmentation, benign lentigines) associated with photodamage.

Use as an adjunct to a comprehensive skin care plan and sun avoidance program. (See Administration under Dosage and Administration.)

Does not eliminate or prevent wrinkles, repair photodamaged skin, reverse photoaging, or restore youthful or younger dermal histologic pattern. No mitigating effects on severe manifestations of chronic sunlight exposure (e.g., coarse/deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, dermal elastosis) demonstrated.

Safety and efficacy not established for use in nonwhite (e.g., Asian, Hispanic) patients or Fitzpatrick skin types V and VI.